<DOC>
	<DOCNO>NCT01892189</DOCNO>
	<brief_summary>The purpose study determine whether ketamine-induced brain activity change modulate TAK-063 administration use neuroimaging battery test .</brief_summary>
	<brief_title>Effects TAK-063 Preventing Ketamine-Induced Brain Activity Changes Well Psychotic-Like Symptoms Healthy Male Adults</brief_title>
	<detailed_description>The drug test study call TAK-063 . This study look brain activity change treatment psychotic-like symptom induce ketamine , people take TAK-063 . The study enroll approximately 27 participant . Participants randomly assign one treatment sequencesâ€”which remain undisclosed participant study ( unless urgent medical need ) . Participants receive follow study medication end study : - Ketamine intravenous infusion ( IV ) AND - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient AND - Two dos TAK-063 one three dose level All participant ask take 3 tablet receive ketamine IV first day 3 separate study period . Participants assess brain activity change symptoms . This single-center trial conduct United States . The overall time participate study 7 week . Participants make 6 visit clinic .</detailed_description>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is healthy adult male . 4 . Speaks English first language . 5 . Is age 18 45 year , inclusive , time informed consent first dose study drug . 6 . Weighs least 50 kg body mass index ( BMI ) 18 32 kilogram per metre square ( kg/m^2 ) , inclusive Screening . 7 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 8 . Has normal magnetic resonance imaging ( MRI ) scan electroencephalogram ( EEG ) measurement Screening . 1 . Has receive investigational compound ketamine within 30 day prior Day 1 Period 1 . 2 . Has receive TAK063 previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 4 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine disease , psychiatric disorder , abnormality ( include MRI EEG ) , may impact ability participant participate potentially confound study result . 5 . Has know hypersensitivity component formulation TAK063 ketamine . 6 . Has contraindication ketamine . 7 . Has positive result drug alcohol Screening Checkin ( Day 1 Period 1 ) . 8 . Has history drug alcohol abuse dependence ( define Diagnostic &amp; Statistical Manual Mental Disorders , fourth Edition [ DSMIV ] ) within 1 year prior screen visit unwilling agree abstain alcohol drug throughout study . 9 . Has take exclude medication , supplement , food product list Excluded Medications Dietary Products . 10 . Has evidence current cardiovascular , central nervous system ( CNS ) , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . There find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take TAK063 ketamine similar drug class , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . 11 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis frequent [ per week ] occurrence heartburn , surgical intervention [ e.g. , cholecystectomy ] ) . 12 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 Period 1 . 13 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) , know history human immunodeficiency virus infection Screening . 14 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 1 Period 1 ) cotinine test positive Screening Checkin ( Day 1 Period 1 ) . 15 . Has poor peripheral arterial/venous access recent wrist trauma . 16 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 3 month prior Day 1 Period 1 . 17 . Has Screening and/or Checkin ( Day 1 Period 1 ) abnormal ( clinically significant ) electrocardiogram ( ECG ) . Participant supine blood pressure outside range 90 140 mm Hg systolic 50 90 mm Hg diastolic , range may repeat eligibility determination Screening Visit Checkin ( Day 1 Period 1 ) . 18 . Has rest heart rate outside range 50 90 beat per minute ( bpm ) , range may repeat eligibility determination Screening Visit and/or Checkin ( Day 1 Period 1 ) . 19 . Has QT interval Fridericia correction method ( QTcF ) great ( &gt; ) 430 millisecond ( m ) PR outside range 120 220 m , range may repeat eligibility determination within maximum 5 minute , Screening Visit and/or Checkin ( Day 1 Period 1 ) . 20 . Has abnormal Screening laboratory value suggest clinically significant underlying disease participant follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5 upper limit normal ( ULN ) . 21 . Has history Axis I/II mental disorder accord DSMIV Axis I/II depression , anxiety disorder , bipolar disorder , attention deficit/hyperactivity disorder ( ADHD ) , autism spectrum disorder , anorexia nervosa , bulimia nervosa , schizophrenia . 22 . Has history head injury trauma . 23 . Has condition would prevent MRI accurately safely perform ( e.g. , claustrophobia , cardiac pacemaker , metallic implant clip ) , verify per study site 's standard MRI assessment questionnaire . 24 . Has risk suicide accord Investigator 's clinical judgment ( e.g. , per ColumbiaSuicide Severity Rating Scale [ CSSRS ] ) make suicide attempt previous 6 month prior Screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>